PAI-1: An Integrator of Cell Signaling and Migration

Cellular migration, over simple surfaces or through complex stromal barriers, requires coordination between detachment/re-adhesion cycles, involving structural components of the extracellular matrix and their surface-binding elements (integrins), and the precise regulation of the pericellular proteolytic microenvironment. It is now apparent that several proteases and protease inhibitors, most notably urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1), also interact with several cell surface receptors transducing intracellular signals that significantly affect both motile and proliferative programs. These events appear distinct from the original function of uPA/PAI-1 as modulators of the plasmin-based proteolytic cascade. The multifaceted interactions of PAI-1 with specific matrix components (i.e., vitronectin), the low-density lipoprotein receptor-related protein-1 (LRP1), and the uPA/uPA receptor complex have dramatic consequences on the migratory phenotype and may underlie the pathophysiologic sequalae of PAI-1 deficiency and overexpression. This paper focuses on the increasingly intricate role of PAI-1 as a major mechanistic determinant of the cellular migratory phenotype.

[1]  R. Czekay,et al.  The Low Density Lipoprotein Receptor-related Protein Is a Motogenic Receptor for Plasminogen Activator Inhibitor-1* , 2004, Journal of Biological Chemistry.

[2]  B. Degryse,et al.  Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein. , 2009, The international journal of biochemistry & cell biology.

[3]  S. Kellouche,et al.  Initial formation of IGROV1 ovarian cancer multicellular aggregates involves vitronectin , 2010, Tumor Biology.

[4]  J. Foidart,et al.  PAI-1 Regulates the Invasive Phenotype in Human Cutaneous Squamous Cell Carcinoma , 2010, Journal of oncology.

[5]  R. Samarakoon,et al.  Integration of non-SMAD and SMAD signaling in TGF-β1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells , 2008, Thrombosis and Haemostasis.

[6]  N. Brünner,et al.  Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  D. Seiffert,et al.  Two functionally distinct pools of vitronectin (Vn) in the blood circulation: identification of a heparin-binding competent population of Vn within platelet alpha-granules. , 1996, Blood.

[8]  M. Jo,et al.  Low Density Lipoprotein Receptor-related Protein (LRP1) Regulates Rac1 and RhoA Reciprocally to Control Schwann Cell Adhesion and Migration* , 2010, The Journal of Biological Chemistry.

[9]  P. Higgins,et al.  PAI‐1 gene expression is regionally induced in wounded epithelial cell monolayers and required for injury repair , 2000, Journal of cellular physiology.

[10]  F. Blasi,et al.  Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes , 1997, The EMBO journal.

[11]  D. Cheresh,et al.  Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. , 1991, The Journal of clinical investigation.

[12]  R. Balsara,et al.  Targeting plasminogen activator inhibitor-1: role in cell signaling and the biology of domain-specific knock-in mice. , 2007, Current drug targets.

[13]  A. Gaultier,et al.  The Hemopexin Domain of Matrix Metalloproteinase-9 Activates Cell Signaling and Promotes Migration of Schwann Cells by Binding to Low-Density Lipoprotein Receptor-Related Protein , 2008, The Journal of Neuroscience.

[14]  R. Aurora,et al.  Modulators of cancer cell invasiveness , 2010, Journal of cellular biochemistry.

[15]  J. Mazurkiewicz,et al.  TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1. , 2009, Cancer research.

[16]  M. Bernfield,et al.  Regulated Shedding of Syndecan-1 and -4 Ectodomains by Thrombin and Growth Factor Receptor Activation* , 1997, The Journal of Biological Chemistry.

[17]  R. Buscà,et al.  Transcriptional Signature of Epidermal Keratinocytes Subjected to in Vitro Scratch Wounding Reveals Selective Roles for ERK1/2, p38, and Phosphatidylinositol 3-Kinase Signaling Pathways* , 2007, Journal of Biological Chemistry.

[18]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[19]  D. Cheresh,et al.  Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. , 1987, The Journal of biological chemistry.

[20]  N. Gibran,et al.  Vitronectin deficiency is associated with increased wound fibrinolysis and decreased microvascular angiogenesis in mice. , 2000, Surgery.

[21]  Craig E. Higgins,et al.  TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. , 2008, Journal of molecular and cellular cardiology.

[22]  P. Andreasen,et al.  Very Low Density Lipoprotein Receptor Binds and Mediates Endocytosis of Urokinase-type Plasminogen Activator-Type-1 Plasminogen Activator Inhibitor Complex (*) , 1995, The Journal of Biological Chemistry.

[23]  S. Hopkinson,et al.  Laminin deposition in the extracellular matrix: a complex picture emerges , 2009, Journal of Cell Science.

[24]  J. Huntington Shape-shifting serpins--advantages of a mobile mechanism. , 2006, Trends in biochemical sciences.

[25]  Y. Wei,et al.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. , 1997, The Journal of clinical investigation.

[26]  W. Campana,et al.  Molecular Dissection of the Human α2-Macroglobulin Subunit Reveals Domains with Antagonistic Activities in Cell Signaling* , 2008, Journal of Biological Chemistry.

[27]  J. Shute,et al.  Plasminogen Activator Inhibitor-1 Supports IL-8-Mediated Neutrophil Transendothelial Migration by Inhibition of the Constitutive Shedding of Endothelial IL-8/Heparan Sulfate/Syndecan-1 Complexes1 , 2003, The Journal of Immunology.

[28]  Stephen P. Higgins,et al.  pAI-1: A Multifunctional seRpIn with complex Roles in cell signaling and Migration , 2010 .

[29]  D. Strickland,et al.  LRP: a multifunctional scavenger and signaling receptor. , 2001, The Journal of clinical investigation.

[30]  N. Perrimon,et al.  The Jak/STAT pathway in model organisms: emerging roles in cell movement. , 2002, Developmental cell.

[31]  P. Andreasen,et al.  Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis , 2004, Thrombosis and Haemostasis.

[32]  D. Cines,et al.  LRP and αvβ3 mediate tPA activation of smooth muscle cells , 2006 .

[33]  I. Mikhailenko,et al.  Low Density Lipoprotein Receptor-related Protein 1 (LRP1) Forms a Signaling Complex with Platelet-derived Growth Factor Receptor-β in Endosomes and Regulates Activation of the MAPK Pathway* , 2010, The Journal of Biological Chemistry.

[34]  D. Lawrence,et al.  Old Dogs and New Tricks, Proteases, Inhibitors, and Cell Migration , 2003, Science's STKE.

[35]  P. Higgins,et al.  PAI‐1 expression is required for epithelial cell migration in two distinct phases of in vitro wound repair , 2004, Journal of cellular physiology.

[36]  D. Lawrence,et al.  Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. , 1994, The Journal of biological chemistry.

[37]  F. Castellino,et al.  Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. , 2000, Cancer research.

[38]  E. Hurt,et al.  Identification of Vitronectin as an Extrinsic Inducer of Cancer Stem Cell Differentiation and Tumor Formation , 2009, Stem cells.

[39]  F. Tang,et al.  Cellular growth inhibition by IGFBP‐3 and TGF‐β1 requires LRP‐1 , 2003 .

[40]  D. Seiffert Constitutive and regulated expression of vitronectin. , 1997, Histology and histopathology.

[41]  Richard G. W. Anderson,et al.  LRP: Role in Vascular Wall Integrity and Protection from Atherosclerosis , 2003, Science.

[42]  E. Ruoslahti,et al.  A 125/115-kDa cell surface receptor specific for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from fibronectin. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Wilcox,et al.  Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. , 1995, Journal of cell science.

[44]  M. Iruela-Arispe,et al.  Distribution of vitronectin mRNA during murine development , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.

[45]  S. Pawar,et al.  Differential gene expression in migrating renal epithelial cells after wounding , 1995, Journal of cellular physiology.

[46]  D. Lawrence,et al.  Plasminogen activator inhibitor‐1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices , 2010, Journal of thrombosis and haemostasis : JTH.

[47]  R. Orlando,et al.  The Low Density Lipoprotein Receptor-related Protein Complexes with Cell Surface Heparan Sulfate Proteoglycans to Regulate Proteoglycan-mediated Lipoprotein Catabolism* , 2003, The Journal of Biological Chemistry.

[48]  D. Loskutoff,et al.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? , 1996, The Journal of cell biology.

[49]  R. Czekay,et al.  Plasminogen activator inhibitor‐1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin , 2001, Journal of cellular physiology.

[50]  P. Charlton,et al.  Plasminogen Activator Inhibitor-1 Supports IL-8-Mediated Neutrophil Transendothelial Migration by Inhibition of the Constitutive Shedding of Endothelial IL-8/Heparan Sulfate/Syndecan-1 Complexes , 2003, The Journal of Immunology.

[51]  P. Carmeliet,et al.  Plasminogen Activator Inhibitor-1 Regulates Integrin αvβ3 Expression and Autocrine Transforming Growth Factor β Signaling* , 2009, The Journal of Biological Chemistry.

[52]  P. McKeown-Longo,et al.  Vitronectin's Basic Domain is a Syndecan Ligand which Functions in transto Regulate Vitronectin Turnover , 2003, Cell communication & adhesion.

[53]  Craig E. Higgins,et al.  PAI-1 mediates the TGF-beta1+EGF-induced "scatter" response in transformed human keratinocytes. , 2010, The Journal of investigative dermatology.

[54]  D. Cheresh,et al.  Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin. , 1990, The Journal of biological chemistry.

[55]  P. Andreasen,et al.  Vitronectin in human breast carcinomas. , 2003, Biochimica et biophysica acta.

[56]  M. Schmitt,et al.  Prognostische Bedeutung des Plasminogenaktivators vom Urokinasetyp (uPA) und des Plasminogenaktivator-Inhibitors (PAI-1) beim primär resezierten Plattenepithelkarzinom der Mundhöhle , 2004, Mund-, Kiefer- und Gesichtschirurgie.

[57]  D. Mock,et al.  Profiling motility signal-specific genes in primary human keratinocytes. , 2008, The Journal of investigative dermatology.

[58]  R. Czekay,et al.  Plasminogen activator inhibitors regulate cell adhesion through a uPAR‐dependent mechanism , 2009, Journal of cellular physiology.

[59]  S. Futaki,et al.  Kinetic Analysis of the Interaction between Vitronectin and the Urokinase Receptor* , 2002, The Journal of Biological Chemistry.

[60]  P. Declerck,et al.  Inactivation of Plasminogen Activator Inhibitor-1 by Specific Proteolysis with Stromelysin-1 (MMP-3)* , 2000, The Journal of Biological Chemistry.

[61]  R. Czekay,et al.  Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins , 2003, The Journal of cell biology.

[62]  G. Inoue,et al.  Ligand Binding to LRP1 Transactivates Trk Receptors by a Src Family Kinase–Dependent Pathway , 2009, Science Signaling.

[63]  Wen-Fang Tseng,et al.  LRP‐1/TβR‐V mediates TGF‐β1‐induced growth inhibition in CHO cells , 2004 .

[64]  R. Czekay,et al.  Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. , 2001, Molecular biology of the cell.

[65]  T. Krieg,et al.  Integrin expression in the dermis during scar formation in humans , 2002, Experimental dermatology.

[66]  Y. Takayama,et al.  LRP1 Regulates Architecture of the Vascular Wall by Controlling PDGFRβ-Dependent Phosphatidylinositol 3-Kinase Activation , 2009, PloS one.

[67]  K. Rubin,et al.  Vitronectin in colorectal adenocarcinoma--synthesis by stromal cells in culture. , 1994, Experimental cell research.

[68]  M. Stack,et al.  Processing of Laminin-5 and Its Functional Consequences: Role of Plasmin and Tissue-type Plasminogen Activator , 1998, The Journal of cell biology.

[69]  D. Cheresh Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[70]  J. Mimuro,et al.  Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. , 1989, The Journal of biological chemistry.

[71]  A. Eddy,et al.  PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. , 2001, Kidney international.

[72]  F. Carreiras,et al.  Mesothelial vitronectin stimulates migration of ovarian cancer cells , 2010, Cell biology international.

[73]  D. Ann,et al.  Crosstalk of hypoxia‐mediated signaling pathways in upregulating plasminogen activator inhibitor‐1 expression in keloid fibroblasts , 2004, Journal of cellular physiology.

[74]  Y. Eguchi,et al.  Detection of vitronectin mRNA in tissues and cells of the mouse. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[75]  S. Hill,et al.  Differential mechanisms targeting type 1 plasminogen activator inhibitor and vitronectin into the storage granules of a human megakaryocytic cell line. , 1996, Blood.

[76]  J. Mimuro,et al.  Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. , 1989, The Journal of biological chemistry.

[77]  P. Declerck,et al.  Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop. , 1994, The Journal of biological chemistry.

[78]  C. Gahmberg,et al.  LDL-receptor-related protein regulates beta2-integrin-mediated leukocyte adhesion. , 2005, Blood.

[79]  M. D. Evans,et al.  Vitronectin is present in epithelial cells of the intact lens and promotes epithelial mesenchymal transition in lens epithelial explants. , 2006, Molecular vision.

[80]  Richard G. W. Anderson,et al.  LRP1 Functions as an Atheroprotective Integrator of TGFβ and PDGF Signals in the Vascular Wall: Implications for Marfan Syndrome , 2007, PloS one.

[81]  K. Itoh,et al.  Induction of glioma cell migration by vitronectin in human serum and cerebrospinal fluid. , 2007, Journal of neurosurgery.